Clinical Trials Logo

Clinical Trial Summary

Background: Vertigo as acute symptom seem to be one of most common presentation in ED, can be treated in ED with multiple medication . Objective: This study aimed to compare the therapeutic efficacy of metoclopramide, promethazine and prochloroperazine in patients presenting with signs and symptoms suggestive of acute peripheral vertigo to the ED . Methods: A 3-arm multi-center, randomized, double-blind, controlled study comparing three treatments for acute vertigo in three medical centers : AlNahdha hospital , Sohar Hospital and AFH hospital. Oman From February 2022 to February 2023.


Clinical Trial Description

- Background Vertigo is one of most ED visit symptoms, It can be due to central or peripheral cause. The most frequent three reasons for vertigo are acute peripheral vestibulopathy (vestibular neuritis, labyrinthitis), Meniere's disease, and benign paroxysmal positional vertigo (BPPV). Usually ED doctors started with Epley maneuver for relief of symptoms and then started with medication. - Objective: This study aimed to compare the therapeutic efficacy of metoclopramide, promethazine and prochloroperazine in patients presenting with signs and symptoms suggestive of acute peripheral vertigo to the ED . • Research methods: This will be done by assessing the Best medication can be used to treat peripheral vertigo with least side effect through Randomized double blinded analysis will use 3 medications. All medications will be saved in similar syringe with white paper cover and labeled as A,B, C .The treating EM Doctor will prescribe medication as anti-vertigo then one of covered medication will be randomly taken among 3 medication groups. Target population will be all patient in age group (18-65) years visiting the emergency department at Al Nahdha hospital, AFH and Sohar hospital who complain of peripheral vertigo after assessment and excluding central cause. Ethical approval will be applied for through the OMSB (Ministry of health ethical committee) ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05586763
Study type Interventional
Source Oman Medical Speciality Board
Contact Asma Al Buraiki, MD
Phone +96896735469
Email asma.b19@resident.omsb.org
Status Recruiting
Phase Phase 3
Start date February 1, 2022
Completion date August 30, 2023

See also
  Status Clinical Trial Phase
Completed NCT01890538 - Comparison of Efficacy Between Piracetam and Dimenhydrinate in Patients With Peripheral Vertigo Phase 4
Recruiting NCT05676216 - Sodium Bicarbonate for Acute Peripheral Vertigo N/A